BrightAccountsProduction v1.0.0 v1.0.0 2025-03-01 The company was not dormant during the period The company was trading for the entire period Unaudited Accounts The principle activity of the company during the period under review was the provision of business and domestic software development. 23 October 2026 3 16285156 2026-03-31 16285156 2025-02-28 16285156 2025-03-01 2026-03-31 16285156 uk-bus:PrivateLimitedCompanyLtd 2025-03-01 2026-03-31 16285156 uk-curr:PoundSterling 2025-03-01 2026-03-31 16285156 uk-bus:SmallCompaniesRegimeForAccounts 2025-03-01 2026-03-31 16285156 uk-bus:FullAccounts 2025-03-01 2026-03-31 16285156 uk-bus:Director1 2025-03-01 2026-03-31 16285156 uk-bus:Director2 2025-03-01 2026-03-31 16285156 uk-bus:Director3 2025-03-01 2026-03-31 16285156 uk-bus:RegisteredOffice 2025-03-01 2026-03-31 16285156 uk-bus:Agent1 2025-03-01 2026-03-31 16285156 uk-core:ShareCapital 2026-03-31 16285156 uk-core:SharePremium 2026-03-31 16285156 uk-core:RetainedEarningsAccumulatedLosses 2026-03-31 16285156 uk-core:TotalEquityAttributableToOwnersParentBeforeNon-controllingInterests 2026-03-31 16285156 uk-bus:FRS102 2025-03-01 2026-03-31 16285156 uk-core:FurnitureFittingsToolsEquipment 2025-03-01 2026-03-31 16285156 uk-core:CurrentFinancialInstruments 2026-03-31 16285156 uk-core:WithinOneYear 2026-03-31 16285156 uk-core:EmployeeBenefits 2025-02-28 16285156 uk-core:EmployeeBenefits 2025-03-01 2026-03-31 16285156 uk-core:AcceleratedTaxDepreciationDeferredTax 2026-03-31 16285156 uk-core:TaxLossesCarry-forwardsDeferredTax 2026-03-31 16285156 uk-core:OtherDeferredTax 2026-03-31 16285156 uk-core:RevaluationPropertyPlantEquipmentDeferredTax 2026-03-31 16285156 uk-core:EmployeeBenefits 2026-03-31 16285156 2025-03-01 2026-03-31 16285156 uk-bus:AuditExempt-NoAccountantsReport 2025-03-01 2026-03-31 xbrli:pure iso4217:GBP xbrli:shares
Company Registration Number: 16285156
 
 
Jigsaw Medical Ltd
 
Unaudited Financial Statements
 
for the financial period from 1 March 2025 (date of incorporation) to 31 March 2026
Jigsaw Medical Ltd
DIRECTORS AND OTHER INFORMATION

 
Directors Dr Grant Switzer Nolan (Appointed 1 March 2025)
Mr James William Henshaw (Appointed 29 May 2025)
Mr Gavin Goldblatt (Appointed 8 October 2025)
 
 
Company Registration Number 16285156
 
 
Registered Office and Business Address 303 Eversleigh Road
London
SW11 5XS
 
 
Accountants Langers
Chartered Certified Accountants
8-10 Gatley Road
Cheadle
Cheshire
SK8 1PY



Jigsaw Medical Ltd
Company Registration Number: 16285156
STATEMENT OF FINANCIAL POSITION
as at 31 March 2026

Mar 26
Notes £
 
Fixed Assets
Tangible assets 5 2,374
─────────
 
Current Assets
Debtors 6 11,329
Cash and cash equivalents 327,805
─────────
339,134
─────────
Creditors: amounts falling due within one year 7 (13,232)
─────────
Net Current Assets 325,902
─────────
Total Assets less Current Liabilities 328,276
 
Provisions for liabilities 8 (451)
─────────
Net Assets 327,825
═════════
 
Capital and Reserves
Called up share capital 1
Share premium account 499,995
Retained earnings (172,171)
─────────
Equity attributable to owners of the company 327,825
═════════
 
The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A (Small Entities).
       
The company has taken advantage of the exemption under section 444 not to file the Income Statement and Directors' Report.
       
For the financial period from 1 March 2025 (date of incorporation) to 31 March 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006.
       
The directors confirm that the members have not required the company to obtain an audit of its financial statements for the financial period in question in accordance with section 476 of the Companies Act 2006.
       
The directors acknowledge their responsibilities for ensuring that the company keeps accounting records which comply with section 386 and for preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial period and of its profit and loss for the financial period in accordance with the requirements of sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.
       
Approved by the Board and authorised for issue on 23 October 2026 and signed on its behalf by
       
       
       
________________________________      
Dr Grant Switzer Nolan      
Director      
       
       
       
________________________________
Mr James William Henshaw
Director
       
       
       
________________________________      
Mr Gavin Goldblatt      
Director      
       



Jigsaw Medical Ltd
NOTES TO THE FINANCIAL STATEMENTS
for the financial period from 1 March 2025 (date of incorporation) to 31 March 2026

   
1. General Information
 
Jigsaw Medical Ltd is a company limited by shares incorporated and registered in the United Kingdom. The registered number of the company is 16285156. The registered office of the company is 303 Eversleigh Road, London, SW11 5XS which is also the principal place of business of the company. The principle activity of the company during the period under review was the provision of business and domestic software development. The financial statements have been presented in Pound (£) which is also the functional currency of the company.
         
2. Summary of Significant Accounting Policies
 
The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.
 
Statement of compliance
The financial statements of the company for the financial period ended 31 March 2026 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2006.
 
Basis of preparation
The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets.
 
Turnover
Turnover comprises the invoice value of goods supplied by the company, exclusive of trade discounts and value added tax.
 
Tangible assets and depreciation
Tangible assets are stated at cost or at valuation, less accumulated depreciation. Cost comprises purchase price and other directly attributable costs. The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:
 
  Fixtures, fittings and equipment - 25% Straight line
 
The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.
 
 
Trade and other debtors
Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.
 
Provisions
Provisions are recognised when the company has a present legal or constructive obligation arising as a result of a past event, it is probable that an outflow of economic benefits will be required to settle the obligation and a reliable estimate can be made. Provisions are measured at the present value of the expenditures expected to be required to settle the obligation using a pre-tax rate that reflects current market assessments of the same value of money and the risks specific to the obligation. The increase in the provision due to passage of time is recognised as interest expense.
 
Trade and other creditors
Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.
 
Employee benefits
The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund.
 
Taxation and deferred taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial period and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Statement of Financial Position date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the Statement of Financial Position date.

 
Ordinary share capital
The ordinary share capital of the company is presented as equity.
   
3. Period of financial statements
 
The financial statements are for the 13 month period from 1 March 2025 (date of incorporation) to 31 March 2026.
     
4. Employees
 
The average monthly number of employees, including directors, during the financial period was 3.
 
  Mar 26
  Number
 
Director 3
  ═════════
       
5. Tangible assets
  Fixtures, Total
  fittings and  
  equipment  
  £ £
Cost
At 1 March 2025 - -
Additions 3,165 3,165
  ───────── ─────────
At 31 March 2026 3,165 3,165
  ───────── ─────────
Depreciation
At 1 March 2025 - -
Charge for the financial period 791 791
  ───────── ─────────
At 31 March 2026 791 791
  ───────── ─────────
Net book value
At 31 March 2026 2,374 2,374
  ═════════ ═════════
     
6. Debtors Mar 26
  £
 
Trade debtors 451
Taxation 2,171
Prepayments and accrued income 8,707
  ─────────
  11,329
  ═════════
     
7. Creditors Mar 26
Amounts falling due within one year £
 
Taxation 10,052
Directors' current accounts 1,725
Accruals 1,455
  ─────────
  13,232
  ═════════
       
8. Provisions for liabilities
 
The amounts provided for deferred taxation are analysed below:
 
  Capital Total
  allowances  
     
    Mar 26
  £ £
 
At financial period start - -
Charged to profit and loss 451 451
  ───────── ─────────
At financial period end 451 451
  ═════════ ═════════
     
9. Capital commitments
 
The company had no material capital commitments at the financial period-ended 31 March 2026.
   
10. Directors' advances, credits and guarantees
 
At 31 March 2026 the company owed the director Grant Nolan £1,725. No interest has been charged to the company in respect of this loan which is repayable on demand and classified in creditors due within one year.
   
11. Events After the End of the Reporting Period
 
There have been no significant events affecting the company since the financial period-end.